Research and Markets: Emerging Markets Series: The Pharmaceutical Market of Saudi Arabia

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/313cab/emerging_markets_s) has
announced the addition of the "Emerging Markets Series: The Pharmaceutical
Market of Saudi Arabia" report to their offering.

The Saudi Arabian pharmaceutical sector is becoming increasingly attractive for
multinationals to enter driven by the expansion of private healthcare and
altering patient demographics; and also for domestic generics companies as the
government looks to evolve its cost saving strategies.

Scope

* Overview of challenges faced by the Saudi Arabian healthcare system and a
review of the healthcare financing system reforms
* Analysis of trends observed in the pharmaceutical sector and the development
of the healthcare insurance sector
* Update of healthcare reforms undertaken in the Kingdom and thought-leader
insights into future changes to be implemented
* Commercial implications of the reforms for insurers, multinational and
domestic pharma companies, supported by Datamonitor strategic recommendations

Highlights of this title:

* Healthcare reforms in Saudi Arabia will increase access to healthcare services
and pharmaceuticals as the penetration of cooperative health insurance increases
across the Kingdom. Datamonitor forecasts this will result in a significant
increase in overall expenditure on drugs; however there will be a greater shift
towards generics use.
* As competition increases, insurers will attempt to increase profits by
implementing cost containment measures such as pharmacoeconomic drug
evaluations, generic substitution and formulary lists. However, strong
underwriting policies, optimal pricing premiums, and delivering quality care to
members will remain critical.
* Increasingly westernized lifestyles have driven up levels of chronic disease,
enhancing the need for drug intervention, with lifestyle products dominating the
retail market. Many branded drugs despite their off patent status still command
market leading sales and positive growth, underlining the preference for branded
drugs in the Saudi market.

Key reasons to purchase this title

* Understand the Saudi healthcare market and the strategic implications of
future reforms and how these will affect your business
* Identify opportunities for mutually beneficial relationships between your firm
and insurers which are becoming increasingly powerful stakeholders
* Gain insight into investment opportunities and create compelling cases for
strategic changes in your organization to adapt to the evolving market

Some of the Key Topics Covered:

EXECUTIVE SUMMARY

OVERVIEW OF THE HEALTHCARE CHALLENGES IN SAUDI ARABIA

* Key findings
* Future challenges facing healthcare in Saudi Arabia
* The growing demographics of Saudi Arabia
* Chronic illnesses are a major concern for authorities in Saudi Arabia

HEALTHCARE FINANCING IN SAUDI ARABIA

* Key findings
* Access to healthcare in Saudi Arabia is currently patchy
* Private healthcare expenditure is set to grow
* Healthcare in Saudi Arabia is primarily delivered through public channels
* Controlling costs in the public sector
* Change in distribution among private funding

HEALTH INSURANCE IN SAUDI ARABIA

* Key findings
* Private versus public healthcare in Saudi Arabia
* The basic private health insurance coverage stipulated for Saudi Arabia is the
best in the region
* The Saudi insurance market will be a strategic growth area as nationals are
included
* The cooperative health insurance sector is a strategic growth area in Saudi
Arabia
* The Saudi healthcare insurance sector is well-regulated
* Key factors affecting growth in the burgeoning Saudi healthcare insurance
market

THE SAUDI ARABIAN PHARMACEUTICAL MARKET

* Key findings
* Pharmaceutical market dynamics in Saudi Arabia
* Pharmaceutical market dynamics in Saudi Arabia
* European drugs dominate the imports in Saudi Arabia
* Saudi generics manufacturers face a number of barriers to growth
* Generic drugs are widely used in the public sector, but not in the private
sector
* Pricing of generics and strong competition limits revenues
* Misleading information on generic medicine inserts impacts uptake
* Pharmacists play a significant and often unregulated role in dispensing of
brands over generics
* Patients are pressurizing physicians to prescribe generics

HEALTHCARE REGULATORY AND GOVERNMENTAL ORGANIZATIONS

* Key findings
* The healthcare sector in Saudi Arabia consists of a complex network of
regulators
* Gulf Co-operative Council Health Ministers Council has been a platform for
developing healthcare in the region
* Gulf Central Committee for Drug Registration
* Bulk purchasing of drugs has been a powerful cost-saving mechanism for Gulf
Cooperation Council governments
* The Ministry of Health is currently undergoing a transition towards a more
regulatory role
* Ministry of Health vaccination programs present opportunities for vaccine
manufacturers
* Combating diabetes will be one of the Ministry of Healths key regulatory
roles

PRICING AND REIMBURSEMENT IN SAUDI ARABIA

* Key findings
* Evolving pricing and reimbursement strategies in Saudi Arabia are required to
control healthcare expenditure
* The Ministry of Health controls drug prices in Saudi Arabia
* Price adjustments were enacted by the Ministry of Health in 2008
* New SFDA recommendations for drug pricing guidelines proposed
* Newly proposed changes to the common pricing criteria
* Pricing guidelines for innovative drugs before and after patent expiry
* Pricing guidelines for generic drugs

BIBLIOGRAPHY

* Journals and online articles

For more information visit
http://www.researchandmarkets.com/research/313cab/emerging_markets_s

Source: Datamonitor

Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2009